Key Takeaway: Precision BioSciences reported its third quarter 2025 financial results, highlighting a late-breaking oral presentation at the Liver Meeting 2025. The presentation will showcase new data from various cohorts of the Phase 1 ELIMINATE-B trial for PBGENE-HBV in chronic hepatitis B. The company has also commenced dosing in Cohort 3, with further data expected in early 2026.
Price reaction · baseline $7.425 (2025-11-03T18:00:00.000Z) · hit during market hours · clean, no other DTIL news in the window
day 0 close · peak
-0.9%
Market Sentiment Analysis
POSITIVE FACTORS
New data from the Phase 1 ELIMINATE-B trial shows promise.
Dosing has commenced in Cohort 3, indicating progress.
Additional data readouts are planned for early 2026.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Late-breaking oral presentation at the Liver Meeting ® 2025 to feature new data from multiple cohorts of the Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B – Commenced dosing in Cohort 3 of the ELIMINATE-B trial with additional data readouts planned in early 2026 – Investigational
Frequently Asked Questions
What is the ELIMINATE-B trial?
The ELIMINATE-B trial is a Phase 1 study evaluating PBGENE-HBV for chronic hepatitis B.
When will additional data from the trial be available?
Additional data readouts from the ELIMINATE-B trial are planned for early 2026.
What was highlighted at the Liver Meeting 2025?
A late-breaking oral presentation will feature new data from multiple cohorts of the trial.
What is the significance of Cohort 3 dosing?
Commencing dosing in Cohort 3 indicates ongoing progress in the ELIMINATE-B trial.